The International Collaboration on Cosmetics Safety opens a new chapter with the selection of its 2026 Board officers, strengthening its worldwide dedication to promoting animal‑free innovations in cosmetics safety science amid swift regulatory and scientific evolution.
The International Collaboration on Cosmetics Safety (ICCS) has finalized its 2026 Board officers following elections conducted during the organization’s December 2025 Board meeting, marking a key step for this relatively young global initiative as it strengthens its role in advancing scientifically rigorous, human-relevant alternatives to animal testing in cosmetics safety evaluation. The newly appointed leadership highlights both consistency and the organization’s increasing maturity, building on a year of notable achievements while preparing to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Acting collectively, the officers make up a Board leadership team whose experience extends across multinational corporations, industry groups, and regulatory science, strengthening ICCS’ role as a neutral forum for cooperation rather than an advocate for any particular sector. This equilibrium underpins the organization’s credibility, especially as it works to shape regulatory perspectives and promote alignment on animal-free safety approaches.
Advancing animal-free science through collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific framework and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to enhance clarity and uniformity in how animal-free safety assessment methods are applied. This guidance sought to close gaps between scientific progress and regulatory requirements, delivering a practical reference that stakeholders could use when generating or reviewing non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
Equally important has been the organization’s focus on sustained dialogue. Throughout 2025, ICCS held extensive exchanges with regulators, scientists, and policymakers in various regions, helping shape conversations on how animal-free data can be evaluated and incorporated within current regulatory systems. These discussions have played a key role in fostering mutual understanding and confidence, especially in places where the regulatory integration of non-animal approaches continues to evolve.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers unfolds amid a period of substantial shifts in global cosmetics regulations, as numerous markets revisit long‑established testing protocols in light of public expectations, scientific progress, and emerging international policy directions, and within this evolving landscape, organizations such as ICCS remain essential in coordinating innovation with regulatory demands so that advancement stays both trustworthy and sustainable.
ICCS leadership has consistently emphasized that the transition to animal-free safety science cannot be achieved through isolated efforts. Instead, it requires coordinated action across industry, academia, regulators, and civil society. The composition of the Board reflects this philosophy, bringing together leaders who understand the technical, regulatory, and organizational dimensions of change.
Statements from ICCS leadership following the elections conveyed a blend of confidence and pragmatism, noting the progress achieved in recent years while recognizing that substantial challenges persist. They emphasized that gaining broad regulatory acceptance for animal-free methods will still demand sustained research investment, open data sharing, and continuous collaboration with authorities to address valid concerns regarding reliability, practical relevance, and the safeguarding of public health.
The re-elected Chair highlighted how crucial it is to draw on ICCS’ global, multi-stakeholder framework to narrow the distance between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applied tools that regulators can confidently use.
Reinforcing the groundwork for lasting impact
As ICCS anticipates 2026 and the years ahead, the organization remains committed to strengthening its accomplishments while broadening its influence. The newly confirmed Board leadership is expected to serve a key role in defining priorities that balance scientific aspiration with practical execution. This involves pinpointing areas requiring further guidance or consensus, supporting the validation and dissemination of emerging methodologies, and encouraging international harmonization to minimize fragmentation in regulatory expectations.
Education remains another key pillar of ICCS’ strategy. By providing accessible, science-based resources and forums for discussion, the organization aims to demystify animal-free safety science and encourage informed decision-making. This is particularly important in a field where misconceptions or uneven understanding can slow progress, even when the underlying science is sound.
The organization’s structure, bringing together leading cosmetics and ingredient manufacturers alongside trade groups, research associations, and animal protection organizations, uniquely positions it to confront these challenges. This broad mix of viewpoints helps keep discussions balanced, well‑rounded, and centered on common objectives rather than limited agendas.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
In confirming its 2026 Board officers, ICCS conveys steadiness while signaling continued progress, with its leadership team offering consistent guidance after a year of tangible accomplishments and the seasoned insight required to steer the upcoming phase of transformation; as scientific advances accelerate and regulatory expectations shift, the organization’s function as a convening force and driving agent for animal-free cosmetics safety science is poised to gain even greater significance.
In the end, the importance of the 2026 Board elections stems not only from the members selected but also from what their leadership conveys: an ongoing dedication to cooperation, scientific rigor, and the responsible evolution of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn vision into enduring results, shaping the future of cosmetics safety in a manner that brings ethics, science, and global public confidence into alignment.
